Liraglutide in Newly Onset Type 1 Diabetes.

NCT01879917 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication liraglutide could help preserve beta-cell function in people who were recently diagnosed with type 1 diabetes.

Status Completed The study has finished.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 65 people

Who can join Ages 18–40 · all sexes

Timeline Started 2014-02 · est. completion 2018-08

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT01879917 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.

Treatments tested

Liraglutide also known as Victoza Drug
Placebo Drug

Saline

Main thing measured	Beta-cell function
Sponsor	Hvidovre University Hospital
Conditions studied	Diabetes Mellitus, Type 1
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01879917 ↗